Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptinyx Inc (APTX)

Aptinyx Inc (APTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 103,707
  • Shares Outstanding, K 33,562
  • Annual Sales, $ 6,570 K
  • Annual Income, $ -53,280 K
  • 60-Month Beta -0.03
  • Price/Sales 16.44
  • Price/Cash Flow N/A
  • Price/Book 0.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.47
  • Number of Estimates 3
  • High Estimate -0.45
  • Low Estimate -0.51
  • Prior Year -0.43
  • Growth Rate Est. (year over year) -9.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.07 +0.65%
on 08/19/19
3.86 -19.95%
on 07/31/19
-0.63 (-16.94%)
since 07/19/19
3-Month
2.88 +7.29%
on 06/07/19
4.05 -23.70%
on 07/05/19
-0.42 (-11.97%)
since 05/17/19
52-Week
2.88 +7.29%
on 06/07/19
32.25 -90.42%
on 09/11/18
-19.72 (-86.45%)
since 08/17/18

Most Recent Stories

More News
Aptinyx Inc. (APTX) Reports Q2 Loss, Lags Revenue Estimates

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 30.77% and -2.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

APTX : 3.09 (-4.04%)
Aptinyx Reports Second Quarter 2019 Financial Results and Highlights

Reported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study

APTX : 3.09 (-4.04%)
Aptinyx to Present at the 2019 Wedbush PacGrow Healthcare Conference

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel,...

APTX : 3.09 (-4.04%)
Aptinyx to Report Second Quarter 2019 Financial Results on Monday, August 12, 2019

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will...

APTX : 3.09 (-4.04%)
Aptinyx's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Aptinyx.

APTX : 3.09 (-4.04%)
Aptinyx Salutes Retiring Chief Scientific Officer and NMDA Receptor Drug Discovery Pioneer, Joseph Moskal

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Joseph Moskal,...

APTX : 3.09 (-4.04%)
Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of...

APTX : 3.09 (-4.04%)
Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain

NYX-2925 demonstrated statistically significant effects on a range of neuroimaging biomarkers and patient-reported outcomes, including pain scores

APTX : 3.09 (-4.04%)
Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update

Four Phase 2 studies expected to be ongoing by year end; multiple data read-outs anticipated in 2019 and 2020

APTX : 3.09 (-4.04%)
Aptinyx Appoints Henry Gosebruch to Its Board of Directors

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Henry...

JPM : 108.27 (-0.39%)
APTX : 3.09 (-4.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade APTX with:

Business Summary

Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in...

See More

Key Turning Points

2nd Resistance Point 3.40
1st Resistance Point 3.24
Last Price 3.09
1st Support Level 3.00
2nd Support Level 2.92

See More

52-Week High 32.25
Fibonacci 61.8% 21.03
Fibonacci 50% 17.57
Fibonacci 38.2% 14.10
Last Price 3.09
52-Week Low 2.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar